Table 6 Comparison the CA result for 2010 and 2022.
From: Re-audit of the use of flumazenil following midazolam-induced conscious sedation
2010 | 2022 | ||
|---|---|---|---|
Method of clinical audit | Prospective (fill in proforma) | Retrospective (Flumazenil Drug book and patient’s record) | |
Duration of audit | 12 weeks (April 2019–June 2019) | 24 weeks (January 2022–June 2022) | |
Total number of Midazolam given | 453 | 665 | |
Total number of Flumazenil given | 32 (7%) | 21 (3.15%) | |
Reasons for Flumazenil use | Emergency | 0 (0%) | 0 (0%) |
Special Care | 8 (25%) | 2 (9.5%) | |
Assist escort | 1 (3%) | 0 (0%) | |
Difficult journey | 0 (0%) | 1 (4.7%) | |
Prolong recovery | 22 (69%) | 9 (42.8%) | |
Post op retching | 1 (3%) | 0 (0%) | |
Others | 0 (0%) | 1 (4.7%) | |
Combine codes | 0 (0%) | 8 (38%) | |
Method of administration of Flumazenil | Intravenous (IV) = 31 | Intravenous (IV) = 21 | |
• Increment dose = 21 | |||
• Bolus dose = 9 | |||
Intranasal (IN) = 1 | |||
Time of sedation with Midazolam | Recorded | Not recorded | |
Time of Flumazenil administration | Recorded | Not recorded | |
Time of discharged | Recorded | Not recorded | |
